rosiglitazone has been researched along with Acute Coronary Syndrome in 3 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (33.33) | 29.6817 |
| 2010's | 2 (66.67) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Chen, ZX; Duan, W; Guo, HB; Jiang, DQ; Kuang, WY; Luo, YM; Wan, XH; Wang, HJ; Xie, LH | 1 |
| Gallagher, AM; Leufkens, HG; Seabroke, S; Smeeth, L; van Staa, TP | 1 |
| Atar, D; Serebruany, VL | 1 |
3 other study(ies) available for rosiglitazone and Acute Coronary Syndrome
| Article | Year |
|---|---|
[Effects of PPAR-gamma agonist rosiglitazone on MMP-9 and TIMP-1 expression of monocyte-derived macrophages isolated from patients with acute coronary syndrome].
Topics: Acute Coronary Syndrome; Aged; Case-Control Studies; Cells, Cultured; Female; Humans; Macrophages; Male; Matrix Metalloproteinase 9; Middle Aged; PPAR gamma; Rosiglitazone; Thiazolidinediones; Tissue Inhibitor of Metalloproteinase-1; Transcription Factor RelA; Vasodilator Agents | 2009 |
Risk of death and cardiovascular outcomes with thiazolidinediones: a study with the general practice research database and secondary care data.
Topics: Acute Coronary Syndrome; Aged; Aged, 80 and over; Cardiovascular Diseases; Cohort Studies; Databases, Factual; Diabetes Complications; Diabetes Mellitus; Female; Heart Failure; Hospitalization; Humans; Insulin; Male; Metformin; Middle Aged; Pioglitazone; Risk; Rosiglitazone; Stroke; Thiazolidinediones; Treatment Outcome | 2011 |
Viewpoint: Central adjudication of myocardial infarction in outcome-driven clinical trials--common patterns in TRITON, RECORD, and PLATO?
Topics: Acute Coronary Syndrome; Adenosine; Cardiovascular Diseases; Clinical Trials, Phase III as Topic; Combined Modality Therapy; Diabetes Mellitus, Type 2; Double-Blind Method; Drug Therapy, Combination; Humans; Hypoglycemic Agents; Judgment; Metformin; Multicenter Studies as Topic; Myocardial Infarction; Observer Variation; Outcome Assessment, Health Care; Percutaneous Coronary Intervention; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Process Assessment, Health Care; Randomized Controlled Trials as Topic; Rosiglitazone; Stroke; Sulfonylurea Compounds; Thiazolidinediones; Thiophenes; Ticagrelor | 2012 |